
Press Releases ·
Exploits the full genetic diversity from multiple blood donors to access a vast immune repertoire for fully human antibody discovery with low immunogenicity risk.
Two-photon holography generates intricate 3D bioprinted scaffolds that can recapitulate complex biology in the form of organoids.
Integrates lab experiments with state-of-the-art machine learning to efficiently guide the discovery of optimal antibody candidates.
Replicates in vivo lymph node processes in vitro using 3D lymph node organoids, enabling rapid and scalable mAb discovery.
Prellis’ EXIS™ platform recaptures human immune biology in 3D-printed organoids for the rapid discovery of diverse antibodies for the next generation of therapeutics.
More About TechnologyWhile machine learning is a powerful tool for antibody discovery, its true potential is unlocked when combined with wet lab characterization and confirmation. This synergistic approach defines our unique methodology and sets us apart.
More About UsOur EXIS™ platform revolutionizes antibody discovery, integrating natural immune processes and advanced AI to navigate the complexity of the human immune repertoire with unmatched precision and speed.
Artificial intelligence is at the core of our operations, enhancing the identification and optimization of antibodies, streamlining the path from lab to clinic.
By mirroring the human immune response in vitro, we access a vast diversity of antibodies, leveraging the natural repertoire with the benefit of an intrinsically low immunogenic risk profile, for therapeutic innovation.
Our advanced two-photon laser bioprinters create organoids with the proper 3D structure to recapture the complex biology of immune responses in vitro.
We tap into the genetic diversity of multiple donors, creating an extensive library of fully human antibodies, each with the potential to become a life-saving therapy.
Strategic collaborations amplify our impact, pairing our technological strengths with leading biotech and pharmaceutical partners to accelerate therapeutic development.
Prellis utilizes its unique expertise and advanced technology to make significant strides in the design and development of novel therapeutic agents that can contribute to enhanced treatment outcomes for a variety of diseases.
Partnering